Isoket (Isosorbide Dinitrate)

Isosorbide dinitrate is a nitric‑oxide donor. After oral absorption, it releases nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of arteries and veins, lowering preload and afterload, and ultimately enhancing myocardial oxygen supply while decreasing cardiac strain.

The dosage of Isoket is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber determines the appropriate strength, frequency, and titration schedule, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for isosorbide dinitrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To request Isoket, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Isoket (isosorbide dinitrate) and other organic nitrates such as nitroglycerin share a similar mechanism of nitric‑oxide release and vasodilation. Isosorbide dinitrate has a longer half‑life, allowing less frequent dosing, whereas nitroglycerin often requires more frequent administration. Both are effective for angina, but individual response and tolerance may differ.

Store Isoket at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Isoket is taken orally as a tablet with a full glass of water. It is usually taken at regular intervals as directed by the prescriber, often with the first dose taken at bedtime to reduce the risk of early‑morning hypotension. Patients should not crush or chew the tablets unless instructed otherwise.

The most serious risks include severe hypotension, syncope, myocardial infarction, methemoglobinemia, and life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience fainting, chest pain, severe dizziness, or signs of an allergic response such as swelling or difficulty breathing.

Isoket is contraindicated in patients with known hypersensitivity to isosorbide dinitrate or other organic nitrates, those with severe hypotension, recent use of phosphodiesterase‑5 inhibitors (e.g., sildenafil), and individuals with certain types of cardiogenic shock. Clinicians must assess each patient’s medical history before initiating therapy.